BG108435A - Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride - Google Patents

Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride

Info

Publication number
BG108435A
BG108435A BG108435A BG10843503A BG108435A BG 108435 A BG108435 A BG 108435A BG 108435 A BG108435 A BG 108435A BG 10843503 A BG10843503 A BG 10843503A BG 108435 A BG108435 A BG 108435A
Authority
BG
Bulgaria
Prior art keywords
alpha
hydrochloride
hydroxybutyl
piperidinyl
acetic acid
Prior art date
Application number
BG108435A
Other languages
Bulgarian (bg)
English (en)
Inventor
Reddy SATYANARAYANA
Rajan Thirumalai
Rao Bhaskara
Original Assignee
Dr. Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of BG108435A publication Critical patent/BG108435A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG108435A 2001-06-18 2003-12-11 Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride BG108435A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN484MA2001 2001-06-18

Publications (1)

Publication Number Publication Date
BG108435A true BG108435A (en) 2004-12-30

Family

ID=34566868

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108435A BG108435A (en) 2001-06-18 2003-12-11 Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride

Country Status (20)

Country Link
EP (2) EP2261209A1 (xx)
JP (2) JP2005507374A (xx)
KR (1) KR20040015734A (xx)
CN (1) CN100390145C (xx)
AU (1) AU2001278094B2 (xx)
BG (1) BG108435A (xx)
BR (1) BR0117054A (xx)
CA (2) CA2646802A1 (xx)
CO (1) CO5540340A2 (xx)
CZ (1) CZ20033358A3 (xx)
EE (1) EE200400010A (xx)
HU (1) HUP0401546A2 (xx)
IL (2) IL159266A0 (xx)
MX (1) MXPA03011728A (xx)
NZ (1) NZ530118A (xx)
PL (1) PL367632A1 (xx)
RU (1) RU2269516C2 (xx)
SK (1) SK15372003A3 (xx)
WO (1) WO2002102777A2 (xx)
ZA (1) ZA200309557B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444456A1 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
MXPA06012281A (es) * 2004-04-26 2007-07-18 Teva Pharma Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
WO2007007347A1 (en) * 2005-07-07 2007-01-18 Wockhardt Limited Industrial process of fexofenadine hydrochloride with controlled side products
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
AU693892B2 (en) * 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
IN191492B (xx) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
GB0018691D0 (en) * 2000-07-28 2000-09-20 Rolabo Sl Process

Also Published As

Publication number Publication date
CN1518540A (zh) 2004-08-04
CA2646802A1 (en) 2002-12-27
CN100390145C (zh) 2008-05-28
JP2008094848A (ja) 2008-04-24
NZ530118A (en) 2007-05-31
KR20040015734A (ko) 2004-02-19
WO2002102777A3 (en) 2003-02-27
JP2005507374A (ja) 2005-03-17
PL367632A1 (en) 2005-03-07
BR0117054A (pt) 2004-07-27
CA2450858A1 (en) 2002-12-27
CA2450858C (en) 2009-04-07
AU2001278094B2 (en) 2006-01-12
RU2269516C2 (ru) 2006-02-10
WO2002102777A8 (en) 2003-10-30
EP2261209A1 (en) 2010-12-15
WO2002102777A2 (en) 2002-12-27
MXPA03011728A (es) 2004-07-08
EP1399422A2 (en) 2004-03-24
CZ20033358A3 (en) 2004-04-14
IL159266A0 (en) 2004-06-01
SK15372003A3 (sk) 2004-08-03
CO5540340A2 (es) 2005-07-29
EE200400010A (et) 2004-02-16
RU2004101045A (ru) 2005-06-27
IL159266A (en) 2010-11-30
HUP0401546A2 (hu) 2004-12-28
ZA200309557B (en) 2004-09-14

Similar Documents

Publication Publication Date Title
FI80447B (fi) Foerfarande foer framstaellning av farmaceutiskt vaerdefulla fenylaettiksyraderivat.
BG108435A (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
NO319873B1 (no) Fremgangsmate for fremstilling av antihistaminiske 4-difenylmetyl/difenylmetoksypiperidinderivater, nye mellomprodukter og anvendelse av disse
TW200734038A (en) Novel dispersant and compositions thereof
JP2009533369A5 (xx)
WO1999059971A1 (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
AU2005272389A1 (en) Novel cyclic aminobenzoic acid derivative
CA2584833A1 (en) Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
EA200801518A1 (ru) Новый способ получения высокочистого полиморфа (i) донепезила гидрохлорида
IL180192A (en) The result of arylamide, its salt and the antifungals that contain them
KR20000064507A (ko) 피페리딘유도체의제조방법
US5166148A (en) 2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JP5673729B2 (ja) 4−置換又は非置換テトラヒドロピラン−4−カルボン酸化合物又はそのエステル化合物の製法
JP2010536713A5 (xx)
CA2429563C (en) Process for the preparation of donepezil
NO20082474L (no) Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav
WO2007144391A1 (en) Process for preparing remifentanil, intermediates thereof, use of said intermediates and processes for their preparation
JP5585822B2 (ja) 光学活性ニペコチン酸誘導体の製造方法
TW200637856A (en) Process for producing thiazolidinedion compound and intermediate thereof
DK1489080T3 (da) Fremgangsmåde til frembringelse af cilostazol
PL353977A1 (en) Method of obtaining 4-[1-hydroxy-4-[4-(hydroxydiphenyldimethyl)-1-piperidinylbutyl]-alpha,alpha-dimethylbenzene acetic acid
AU2008288430A1 (en) Novel preparation process
ZA200007034B (en) Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof.
WO2006013049A3 (en) Benzyloxy derivatives as maob inhibitors